REPL replimune.com: Enterprise Value to EBITDA Ratio

Graphic logo of Replimune (REPL)

The EV/EBITDA price chart for Replimune Group, Inc. (REPL) on the GURU.Markets platform is currently at 0.00. Replimune Group, Inc. (REPL) develops anti-tumor agents while adhering to strict environmental standards and bioethics. Business growth relies on partnerships with pharma behemoths for clinical trials; however, the high probability of clinical failure creates significant risks for invested capital.

Replimune Corp - REPL Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for replimune.com (REPL)

- stock price and consensus target price:
Stock Quotes Replimune Corp|REPL - Average Forecast Price
- company stock capitalization data:
Market Valuation Replimune Inc.|REPL - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Replimune|REPL - Book Valuation of Business|Market Value to Book Value Ratio replimune.com|REPL - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Replimune Group, Inc.|REPL - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Replimune|REPL - Company Aggregate Debts|Debt to Book Capitalization Ratio Replimune Inc.|REPL - Company Long-Term Indebtedness|Company Short-Term Debt Replimune|Quick Liquidity Indicator replimune.com
- financial results and valuation multiples details:
REPL - Annual Net Income|Future Profit Replimune Group, Inc.|REPL - Market Price to Net Income Ratio|Forward P/E Multiple Replimune Group, Inc.|REPL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Replimune Inc.|REPL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Replimune|REPL - Earnings per share for the trailing year|Quarterly EPS earnings growth replimune.com|REPL - Earnings growth in current year|Net earnings per share growth forecast for next year Replimune Group, Inc.
Fundamental company analysis:REPL (Replimune Corp)
Original product of Replimune Group Inc

For Replimune Group, Inc. (REPL), whose success depends on the outcomes of vaccine clinical trials, the EV/EBITDA multiple serves as a tool for valuing the business relative to its operating profit. This metric aggregates market capitalization and net debt, comparing them against earnings before depreciation and amortization. By analyzing the historical EV/EBITDA value, an investor can see the current level of 0.00, which reflects market expectations. This allows for an assessment of the company's resilience regardless of macroeconomic cycles.

Competitor analysis for Replimune Group, Inc.

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Lyell Immunopharma, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma SA IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation NEXI (neximmune.com)|TSBX: EV/EBITDA Multiple|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx